166 related articles for article (PubMed ID: 21965764)
1. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lin CH; Lee H; Cheng YW
Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
[TBL] [Abstract][Full Text] [Related]
2. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Liu X; Zhou B; Xue L; Yen F; Chu P; Un F; Yen Y
Clin Colorectal Cancer; 2007 Jan; 6(5):374-81. PubMed ID: 17311703
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Liu X; Zhou B; Xue L; Shih J; Tye K; Lin W; Qi C; Chu P; Un F; Wen W; Yen Y
Clin Cancer Res; 2006 Nov; 12(21):6337-44. PubMed ID: 17085643
[TBL] [Abstract][Full Text] [Related]
4. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Uramoto H; Sugio K; Oyama T; Hanagiri T; Yasumoto K
Anticancer Res; 2006; 26(2A):983-8. PubMed ID: 16619496
[TBL] [Abstract][Full Text] [Related]
5. Redox property of ribonucleotide reductase small subunit M2 and p53R2.
Liu X; Xue L; Yen Y
Methods Mol Biol; 2008; 477():195-206. PubMed ID: 19082948
[TBL] [Abstract][Full Text] [Related]
6. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
7. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
Xue L; Zhou B; Liu X; Qiu W; Jin Z; Yen Y
Cancer Res; 2003 Mar; 63(5):980-6. PubMed ID: 12615712
[TBL] [Abstract][Full Text] [Related]
8. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.
Chen J; Xiao Y; Cai X; Liu J; Chen K; Zhang X
BMC Cancer; 2017 Dec; 17(1):855. PubMed ID: 29246119
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
12. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients.
Kato T; Daigo Y; Aragaki M; Ishikawa K; Sato M; Kondo S; Kaji M
Lung Cancer; 2011 Oct; 74(1):124-31. PubMed ID: 21376419
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
15. p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.
Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lee H; Cheng YW
Oncol Lett; 2010 Jul; 1(4):609-613. PubMed ID: 22966352
[TBL] [Abstract][Full Text] [Related]
16. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.
Qiu W; Zhou B; Darwish D; Shao J; Yen Y
Biochem Biophys Res Commun; 2006 Feb; 340(2):428-34. PubMed ID: 16376858
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Yokomakura N; Kita Y; Matsumoto M; Uchikado Y; Setoyama T; Owaki T; Ishigami S; Aikou T
Clin Cancer Res; 2006 Jun; 12(12):3740-5. PubMed ID: 16778101
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.
Marchetti A; Bertacca G; Buttitta F; Chella A; Quattrocolo G; Angeletti CA; Bevilacqua G
Clin Cancer Res; 1999 Aug; 5(8):2077-81. PubMed ID: 10473089
[TBL] [Abstract][Full Text] [Related]
19. Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer.
Chen CY; Hsu CP; Hsu NY; Shih CS; Lin TY; Chow KC
Oncol Rep; 2002; 9(3):515-9. PubMed ID: 11956619
[TBL] [Abstract][Full Text] [Related]
20. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
